Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study

Published:2021-03-01 Issue:2 Volume:68 Page:173-180
ISSN:0912-0009
Container-title:Journal of Clinical Biochemistry and Nutrition
language:en
Short-container-title:J. Clin. Biochem. Nutr.

Author:

Tobita Hiroshi¹²,Yazaki Tomotaka¹²,Kataoka Masatoshi¹²,Kotani Satoshi²,Oka Akihiko²,Mishiro Tsuyoshi²,Oshima Naoki²,Kawashima Kousaku²,Ishimura Norihisa²,Naora Kohji³,Sato Shuichi⁴,Ishihara Shunji²

Affiliation:

1. Division of Hepatology, Shimane University Hospital

2. Department of Internal Medicine II, Shimane University School of Medicine

3. Department of Pharmacy, Shimane University Hospital

4. Department of International Medicine, Izumo City General Medical Center

Publisher

The Society for Free Radical Research Japan

Subject

Clinical Biochemistry,Nutrition and Dietetics,Medicine (miscellaneous)

Link

https://www.jstage.jst.go.jp/article/jcbn/68/2/68_20-129/_pdf

Reference59 articles.

1. 1 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.

2. 2 Eguchi Y, Hyogo H, Ono M, et al.; JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012; 47: 586–595.

3. 3 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–1419.

4. 4 Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Gastroenterol Hepatol 2009; 7: 234–238.

5. 5 Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389–397.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions;Nutrients;2024-07-11

2. Dapagliflozin ameliorates hepatic steatosis via suppressing LXRα-mediated synthesis of lipids and bile acids;Biochemical Pharmacology;2024-05

3. Applications of SGLT2 inhibitors beyond glycaemic control;Nature Reviews Nephrology;2024-04-26

4. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies;Pharmacological Reviews;2024-01-30

5. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis;Scientific Reports;2024-01-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3